Clinical trials: Neoplasms, Neuroepithelial
Glioblastoma
Safety and Efficacy of Different Administration Sequences of L19TNF With Lomustine in Glioblastoma at First Progression
Open label phase I study in subjects with glioblastoma at first progression to explore two different administration schedules of lomustine for the combination with L19TNF (ARM 1 and ARM 2).
- Trial name
- GLIOASTRA (NCT05304663)
- Testing
- Onfekafusp alfa, Lomustine
- Sponsor
- Philogen S.p.A.
Glioblastoma Multiforme
ADCTA for Adjuvant Immunotherapy in Standard Treatment of Recurrent Glioblastoma Multiforme (GBM)
To confirm the result of previous Phase I/II and phase II clinical trials, this trial is to test the efficacy and safety of ADCTA immunotherapy plus the standard therapy in comparison with standard therapy alone in patients with…
- Trial name
- NCT04277221
- Testing
- Autologous Dendritic Cell/Tumor Antigen, ADCTA
- Where
- 7 sites in Taiwan
- Volunteers
- 118 people
- Sponsor
- Safe Save Medical Cell Sciences & Technology Co.,Ltd.
Glioma
Supratotal Resection for Gliomas Within Noneloquent Areas
Gliomas, especially high grade gliomas and diffuse low grade gliomas, are characterized by their infiltrative nature. Recently, a new conception of supratotal resection has been proposed.
- Trial name
- NCT02676687
- Testing
- total resection, supratotal resection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Southwest Hospital, China
Astrocytoma, Grade II, Astrocytoma, Grade III
FORWARD Optune and Adjuvant TMZ in Grade II/III Astrocytoma
This is a phase 2, multi-institutional, historically-controlled, study of 100 patients with newly diagnosed Grade II and III astrocytoma comparing the combination of TTFields with adjuvant temozolomide versus temozolomide alone…
- Trial name
- FORWARD (NCT03906448)
- Testing
- TTFields with adjuvant temozolomide
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Florida
Brain and Central Nervous System Tumors
Combination Chemotherapy for Patients With Brain Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002814
- Testing
- filgrastim, paclitaxel, topotecan hydrochloride
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Glioblastoma
MRI-Guided Laser Surgery and Doxorubicin Hydrochloride in Treating Patients With Recurrent Glioblastoma Multiforme
This pilot clinical trial studies magnetic resonance imaging (MRI)-guided laser surgery (MLA) and doxorubicin hydrochloride in treating patients with recurrent glioblastoma multiforme.
- Trial name
- NCT01851733
- Testing
- MRI-guided Laser Heat Ablation (MLA), Doxorubicin, Blood draw - dendritic cells
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Washington University School of Medicine
Glioma, Recurrence
Vorasidenib Expanded Access Program
This is an expanded access program to provide vorasidenib for treatment of patients 12 years or older with IDH1- or IDH2-mutated glioma.
- Conditions
- Glioma, Recurrence, Disease Attributes, Pathologic Processes
- Trial name
- NCT05592743
- Testing
- Vorasidenib
- Sponsor
- Servier
Refractory Neuroblastoma, Relapsed Neuroblastoma
GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma
This is a first in human dose escalation trial to determine the safety of administering GPC2 CAR T cells in patients with advanced neuroblastoma or retinoblastoma.
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma, Retinoblastoma
- Trial name
- GPC2 (NCT05650749)
- Testing
- GPC2 CAR T cells
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stephan Grupp MD PhD
Brain and Central Nervous System Tumors
Karenitecin in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of karenitecin in treating patients who have recurrent…
- Trial name
- NCT00014521
- Testing
- karenitecin
- Where
- 8 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma
An Efficacy Study Of Ortataxel In Recurrent Glioblastoma
Italian Study On The Efficacy Of Ortataxel In Recurrent Glioblastoma
- Trial name
- Ortataxel (NCT01989884)
- Testing
- Ortataxel
- Where
- 7 sites in Italy
- Volunteers
- 45 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Glioblastoma Multiforme
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma
Glioblastoma multiforme (GBM) is the most common brain tumor in adults. The strikingly poor survival for patients with GBM (average survival 14-16 months following diagnosis) is due in part to limited early detection methods and…
- Trial name
- NCT04530006
- Testing
- Amantadine Hydrochloride
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- CancerCare Manitoba
Glioma
A Study in Subjects With Recurrent Malignant Glioma
An open-label phase 2, multicenter study in participants with recurrent malignant glioma.
- Trial name
- NCT01137604
- Testing
- Lenvatinib, Bevacizumab
- Where
- 5 sites in United States, Canada
- Volunteers
- 151 people
- Sponsor
- Eisai Inc.
Neuroendocrine Tumors, Neoplasms
Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs
The goal of this study is to establish maximum tolerated doses/recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug…
- Conditions
- Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
- Trial name
- NCT02943733
- Testing
- TAS-102, Temozolomide, Filgrastim
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Wisconsin, Madison
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Brain and Central Nervous System Tumors
Combination Chemotherapy and Radiation Therapy in Treating Younger Patients Who Are Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Gliomas
RATIONALE: Drugs used in chemotherapy, such as temozolomide, busulfan, and O6-benzylguanine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00253487
- Testing
- O6-benzylguanine, busulfan, temozolomide
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glioblastoma
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
This study is for patients with newly diagnosed glioblastoma, as well as patients who have recurring glioblastoma. Subjects will be given daily paxalisib and metformin while also maintaining a ketogenic diet.
- Trial name
- NCT05183204
- Testing
- Paxalisib, Metformin, Ketogenic Diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Glioblastoma Multiforme
Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan
The overall purpose of the study is to investigate the efficacy and safety of ALECSAT in patients with relapse of GlioBlastoma Multiforme (GBM) after first line treatments (followed by reoperation if possible).
- Trial name
- NCT02060955
- Testing
- ALECSAT, Bevacizumab/Irinotecan
- Where
- 4 sites in Denmark
- Volunteers
- 25 people
- Sponsor
- CytoVac A/S
Glioblastoma Multiforme
ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy
The purpose of this study is to evaluate the safety of the ExAblate Model 4000 Type 2.0 used as a tool to disrupt the BBB in patients with Glioblastoma undergoing standard of care therapy.
- Trial name
- NCT03712293
- Testing
- BBB Disruption with Chemotherapy Arm
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- InSightec
Glioblastoma
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
CENTRIC is a Phase 3 clinical trial assessing efficacy and safety of the investigational integrin inhibitor, cilengitide, in combination with standard treatment versus standard treatment alone in newly diagnosed glioblastoma…
- Trial name
- CENTRIC (NCT00689221)
- Testing
- Cilengitide, Temozolomide, Radiotherapy
- Where
- 2 sites in United States, Germany
- Volunteers
- 545 people
- Sponsor
- EMD Serono
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center